Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

I

- 1		
	OMB Number:	3235-0287
	Estimated average bu	irden
	hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1										
1. Name and Addre <u>Young Caroli</u>	ss of Reporting Pers <u>ne</u>	son*	2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [CPIX]		ationship of Reporting Per (all applicable) Director Officer (give title	rson(s) to Issuer 10% Owner Other (specify below)				
(Last) 1600 WEST EN	(First) D AVENUE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/24/2023		below)					
SUITE 1300			4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	,					
					Form filed by One Reporting Person					
(Street) NASHVILLE	TN	37203			Form filed by More that Person	n One Reporting				
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication							
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2A. Deemed Execution Date, 2. Transaction Date 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 5. Amount of Securities 6. Ownership Form: Direct 7. Nature o. Transaction of Indirect Beneficially Owned Following (Month/Day/Year) if any (Month/Day/Year) Code (Instr. 8) 5) (D) or Indirect Beneficial (I) (Instr. 4) Ownership Reported (Instr. 4) (A) or (D) Transaction(s) Code v Price Amount (Instr. 3 and 4) Common Stock 03/24/2023 А 1,000(1) A \$1.97 20,587 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Restricted stock award will vest 100% on March 24, 2024.

Remarks:

Caroline Young by /s/ John

Hamm as attorney-in-fact

** Signature of Reporting Person

03/27/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date